Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01843114
Other study ID # OPHT-280113
Secondary ID
Status Completed
Phase N/A
First received April 26, 2013
Last updated March 17, 2017
Start date January 12, 2015
Est. completion date March 1, 2017

Study information

Verified date March 2017
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The prevalence of diabetes and diabetes-associated complications is still increasing. Several major long-term complications of diabetes such as cardiovascular disease, chronic renal failure, diabetic retinopathy and others relate to the damage of blood vessels. Given that the eye provides the unique possibility in the human body to directly visualize blood vessels, much interest has been directed towards studying the ocular circulation. Although data of large epidemiological studies indicate that changes in retinal vessel caliber reflect other diabetes related factors, such as fasting glucose levels, there is still conflicting evidence on blood flow alterations in patients with diabetes. This is also related to the fact that up to now, methodological difficulties aggravate the assessment of blood flow changes in the retina in larger groups of patients. In the present study we propose to overcome this problem by using a technique called bi-directional Fourier Domain Doppler Optical Coherence Tomography (FDOCT), which we have developed in the recent years to measure retinal blood velocities. This technique allows for the non-invasive investigation of blood flow changes in human retina and will help us to better understand diabetes related vascular changes. The present study will use this technique to assess retinal blood flow changes in patients with diabetes and healthy subjects.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date March 1, 2017
Est. primary completion date August 26, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Inclusion criteria for healthy subjects

- Men and women aged over 18 years

- Non-smokers

- Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant

- Normal ophthalmic findings, ametropia < 6 Dpt.

Inclusion criteria for patients with diabetes

- Men and women aged over 18 years

- Non-smokers

- Previously diagnosed type I diabetes

- No or mild non-proliferative diabetic retinopathy

- Normal ophthalmic findings except mild diabetic retinopathy, ametropia < 6 Dpt.

Exclusion Criteria:

Any of the following will exclude a healthy subject from the study:

- Symptoms of a clinically relevant illness in the 3 weeks before the first study day

- Presence or history of a severe medical condition as judged by the clinical investigator

- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study (except oral contraceptive)

- Arterial hypertension (defined as either systolic blood pressure >145 mmHg or diastolic blood pressure >90 mmHg)

- Blood donation during the previous three weeks

- Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator

- Best corrected visual acuity < 0.8 Snellen

- Ametropia >= 6 Dpt

- Pregnancy, planned pregnancy or lactating

Any of the following will exclude a patient with diabetes from the study:

- Participation in a clinical trial in the 3 weeks preceding the screening visit

- Symptoms of a clinically relevant illness in the 3 weeks before the first study day

- Presence or history of a severe medical condition, except diabetes, as judged by the clinical investigator

- Arterial hypertension (defined as either systolic blood pressure >145 mmHg or diastolic blood pressure >90 mmHg)

- Blood donation during the previous three weeks

- Moderate to severe non-proliferative or proliferative diabetic retinopathy

- Previous laser photocoagulation treatment

- Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator

- Best corrected visual acuity < 0.8 Snellen

- Ametropia >= 6 Dpt

- Pregnancy, planned pregnancy or lactating

Study Design


Intervention

Device:
FDOCT
Measurement of retinal blood velocities
Other:
Dynamic Vessel Analyzer
Measurement of retinal vessel diameters

Locations

Country Name City State
Austria Department of Clinical Pharmacology Vienna

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total retinal blood flow Measurement of total retinal blood flow using the Dynamic Vessel Analyzer and Optical Coherence Tomography 1 day
Secondary Retinal vessel diameter Measurement of retinal vessel diameter using the Dynamic Vessel Analyzer 1 day
Secondary Retinal blood velocities Measurement of retinal blood flow velocities using Fourier Domain Optical Coherence Tomography 1 day
See also
  Status Clinical Trial Phase
Completed NCT05160142 - Diabetes Inspired Culinary Education Early Phase 1
Withdrawn NCT05035368 - Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes Phase 2
Completed NCT01928329 - A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes Phase 2
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Completed NCT00999375 - Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF) Phase 2
Completed NCT04279613 - A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Phase 1
Not yet recruiting NCT02117518 - Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients N/A
Withdrawn NCT01477476 - Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes Phase 2
Terminated NCT01308437 - Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics Phase 3
Terminated NCT01652911 - A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation Phase 1/Phase 2
Completed NCT06242548 - How Type I Diabetes Responds to Different Diets (Normoglucidic or Ketogenic) During Physical Activity at Altitude N/A
Completed NCT00351650 - Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan N/A
Withdrawn NCT00361608 - Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device N/A
Terminated NCT03653533 - Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump N/A
Completed NCT00340639 - Management of Type 1 Diabetes Among Adolescents N/A
Completed NCT02002130 - The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes Phase 1
Completed NCT02634216 - Effects of Capros in Patients With Type-1 Diabetes N/A
Withdrawn NCT01623388 - Epigenetic Modifications of Diabetes Mellitus Type I N/A
Completed NCT02612493 - Obesity and Metabolic Surgery in Patients With Type I Diabetes N/A
Withdrawn NCT01398670 - Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics Phase 3